89 patents
Page 4 of 5
Utility
Nonracemic Mixtures and Uses Thereof
29 Jul 20
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 12 Apr 20
Utility
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
6 Jul 20
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed.
Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
Filed: 9 May 19
Utility
Methods of Treating Neurological and Psychiatric Disorders
10 Jun 20
Seth Cabot HOPKINS
Filed: 4 Dec 19
Utility
Crystal Forms and Production Methods Thereof
27 May 20
The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same.
John R. Snoonian, Harold Scott Wilkinson
Filed: 21 Jan 20
Utility
Nonracemic mixtures and uses thereof
25 May 20
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 8 Jan 20
Utility
Nonracemic Mixtures and Uses Thereof
13 May 20
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 8 Jan 20
Utility
Metabotrophic glutamate receptor 5 modulators and methods use thereof
4 May 20
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
Filed: 5 Dec 18
Utility
Methods of Treating Schizophrenia
29 Apr 20
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia.
Seth HOPKINS, Kenneth KOBLAN, Antony LOEBEL, Ajay OGIRALA
Filed: 15 Feb 18
Utility
CorrectedMetabotrophic Glutamate Receptor 5 Modulators and Methods Use Thereof
11 Mar 20
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
Filed: 5 Dec 18
Utility
Methods of Treating Parkinson's Disease by Administration of Apomorphine to an Oral Mucosa
4 Mar 20
Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described.
Scott David BARNHART, Michael Clinton KOONS, Madhu Sudan HARIHARAN, Jordan DUBOW, Thierry BILBAULT, Anthony John GIOVINAZZO
Filed: 8 Sep 19
Utility
Nonracemic mixtures and uses thereof
2 Mar 20
Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
Filed: 25 Jun 19
Utility
Crystal forms and production methods thereof
2 Mar 20
The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same.
John R. Snoonian, Harold Scott Wilkinson
Filed: 20 Jun 19
Utility
Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors
24 Feb 20
Provided herein are cyclic nucleotide phosphodiesterase inhibitors of Formula (I) of claim 1, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
John Emmerson Campbell, Philip Wendell Jones, Michael Charles Hewitt
Filed: 19 Nov 17
Utility
Cycloalkylamines as monoamine reuptake inhibitors
17 Feb 20
The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis.
Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campell
Filed: 7 Dec 17
Utility
Substituted quinoxalines as PDE-10 inhibitors
17 Feb 20
Provided herein are cyclic nucleotide phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
John Emmerson Campbell, Michael Charles Hewitt, Philip Xinhe Jones, Linghong Xie
Filed: 18 Oct 17
Utility
Heteroaryl compounds and methods of use thereof
10 Feb 20
Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use.
John Emmerson Campbell, Una Campbell, Taleen G. Hanania, Liming Shao
Filed: 21 Dec 17
Utility
Sublingual Apomorphine
29 Jan 20
The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
Anthony John GIOVINAZZO, David Bruce HEDDEN, Marc L. DE SOMER, Nathan John BRYSON
Filed: 7 Aug 19
Utility
Fused DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL Compounds and Analogs for Treating CNS Disorders
22 Jan 20
Milan CHYTIL, Sharon ENGEL, Taleen G. HANANIA, Vadim ALEXANDROV, Emer LEAHY
Filed: 5 May 19
Utility
Metabotrophic glutamate receptor 5 modulators and methods of use thereof
13 Jan 20
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat
Filed: 24 May 12
Utility
TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE
1 Jan 20
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed.
Thomas JERUSSI, Qun Kevin FANG, Mark G CURRIE
Filed: 9 May 19